Following a translational approach using knowledge from non-human primate studies, we are using novel methodological approaches from neurophysiology, brain imaging (fMRI, EEG, MEG), brain stimulation (tDCS, TMS), and molecular genetics both in healthy individuals and clinical patient populations. Alterations in biological markers are used to guide novel treatment approaches to be applied to specific clusters of biomarkers. In our more clinically focussed work, we are interested in processes enhancing treatment adherence based on cognitive behavioral therapy. On an international level, we are collaborating with colleagues across Europe (PRONIA), the U.S. (B-SNIP), Canada (U of Western Ontario), Australia (Western Sydney U) and also China (Chengdu University).
See also collaboration with Westfälische Whilhelms-Universität Münster